HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunscreen use study

This article was originally published in The Rose Sheet

Executive Summary

Approximately 39% of 11-18 year-olds surveyed report receiving their worst summer sunburn after applying sunscreen with SPF 15 or greater, according to a study by Kourtney Davis, PhD, GlaxoSmithKline, and researchers from the American Cancer Society. Approximately 79% of 1,192 youths polled from July through October 1998 experienced at least one sunburn during the time period; 11.9% reported five or more, according to the study, which relied on self-reported data from subjects. "There is a real need for better education and awareness of proper use of these lotions," Davis et al. conclude, noting "If youths are getting their worst burns while using SPF 15 or greater sunscreens, then they are not using them correctly." Study was published in the July issue of Pediatrics...

You may also be interested in...



Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel